Recently, a phase 0 clinical trial evaluating a STAT3 decoy oligonucleotide demonstrated decreased expression of STAT3 target genes in head and neck tumors following intratumoral injection [9]. This evidence concerns the gene STAT3 and head and neck neoplasm.